Company / Revenue
Denali Therapeutics Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
-
FY2025
5-year range
$0 / $335.7M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#147 of 155
Health Care
What the data says
Declined from $331M to $0 over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 155
▼
Key checks
Key Insights
- Peak revenue was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | - |
| FY2024 | $0 | -100.0% |
| FY2023 | $330.5M | -1.5% |
| FY2022 | $335.7M | +1158.2% |
| FY2021 | $26.7M | -79.3% |
| FY2020 | $129.2M | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
| FY2017 | $0 | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026